We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease (LIVERPEARL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04595266
Recruitment Status : Recruiting
First Posted : October 20, 2020
Last Update Posted : January 11, 2022
Sponsor:
Information provided by (Responsible Party):
Grupo Espanol Multidisciplinario del Cancer Digestivo

Brief Summary:

Non-commercial, prospective, randomized, multicenter, national, phase II, open-label comparative clinical trial.

The patients will be randomized in a 1: 1 ratio in two arms:

Control arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab Experimental arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.

The main objective is to evaluate the radiological objective response rate according to the RECIST version 1.1 criteria at 6 months. Secondary objectives include: Evaluate overall survival, progression-free survival (PFS), safety profile, hepatic PFS, R0 liver surgery rate.


Condition or disease Intervention/treatment Phase
Colorectal Cancer Metastatic Liver Metastasis Colon Cancer Drug: FOLFOX regimen Biological: Anti-EGFR or Bevacizumab Drug: LIVERPEARLS-Irinotecan Phase 2

Detailed Description:

Hepatic intra-arterial therapy (TACE) with irinotecan has been used in several prospective studies demonstrating an acceptable toxicity profile. Two randomized phase II studies have evaluated the efficacy of TACE with irinotecan compared to conventional chemotherapy in metastatic colon cancer. A second-line treatment study demonstrated an increase in PFS in the TACE versus FOLFIRI treatment arm.

A prospective open, randomized, multicenter phase II study is proposed that will include patients with liver metastases of colorectal origin with poor prognostic criteria.

LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. The device uses 100 +/- 50 micron microspheres of hydrogel into which chemotherapeutic agents are loaded and delivered into the hepatic artery to treat liver tumors. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.

Systemic treatment will be administered according to the usual guidelines:

-FOLFOX6m for 6 months + monoclonal Ab (cycles are repeated every 15 days) Premedication: Dexamethasone 20 mg IV + ondansetron 8mg IV

The dose of FOLFOX will be:

Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.

Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1. In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.

In the combination arm of systemic chemotherapy with IRINOPEARL, in the 2nd and 4th cycles, chemotherapy will be replaced by treatment with hepatic chemoembolization with IRINOPEARL.

The disease will be evaluated by CT or MRI at baseline and every 12 weeks until progression according to RECIST 1.1 criteria.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

Patients will be randomized in a 1: 1 ratio in the 2 arms:

Control Arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab Experimental Arm. Systemic chemotherapy with FOLFOX6m + monoclonal Ab + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Randomized, Multicenter Phase II Study of Monoclonal FOLFOX6m + mAb Alone or in Combination With Liver Chemoembolization (Lifepearls-Irinotecan) in Patients With Colorectal Cancer and Metastatic Disease Limited to the Liver With Poor Prognosis
Actual Study Start Date : June 29, 2021
Estimated Primary Completion Date : January 2023
Estimated Study Completion Date : January 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: Control
Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab).
Drug: FOLFOX regimen

Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.

Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1

Other Name: Leucovorin/Fluorouracil/Oxaliplatin

Biological: Anti-EGFR or Bevacizumab

In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.

Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications.

Other Name: monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut)

Experimental: Experimental
Systemic chemotherapy with FOLFOX6m + monoclonal Ab (anti-EGFR or bevacizumab) + Intra-arterial liver chemotherapy with LIFEPEARLS-IRINOTECAN (catheterization and infusion of 100 +/- 50 micron microspheres loaded with 100 mg of irinotecan in both liver lobes) cycles 2 and 4.
Drug: FOLFOX regimen

Leucovorin: 400 mg / m2 IV over 15 minutes on day 1 of each cycle. Fluorouracil (5-FU): 400mg / m2 IV bolus (15 min) followed by continuous IV infusion for 46 h of 2,400 mg / m2 on day 1 of each cycle.

Oxaliplatin 85 mg / m2 IV over 120 minutes on cycle day 1

Other Name: Leucovorin/Fluorouracil/Oxaliplatin

Biological: Anti-EGFR or Bevacizumab

In case of RAS wt colorectal cancer administer anti-EGFR together with FOLFOX6m, and in case of mutated RAS colorectal cancer administer Bevacizumab together with FOLFOX6m.

Treatment administered following Summary of medicinal Product Characteristics (SmPC) approved indications.

Other Name: monoclonal antibody anti EGFR (RASwt) or Bevacizumab (RASmut)

Drug: LIVERPEARLS-Irinotecan
Chemoembolization of Irinotecan in 100 +/- 50 micron hydrogel microspheres. Irinotecan will be loaded at a dose of 100 mg. LIFEPEARLS® is a CE marked medical device consisting of microspheres for use in chemoembolization. This device allows the continuous release of irinotecan in liver tumors causing a specific necrosis. The penetration of irinotecan into the tumor tissue is deeper thanks to the microspheres, avoiding proximal occlusion of the vessels supplying the tumor.
Other Name: Chemoembolization of Irinotecan in hydrogel microspheres




Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: Evaluated at 6 months after first investigation drug administration. ]
    The proportion of patients with tumor size reduction according to RECIST 1.1 criteria at 6 months


Secondary Outcome Measures :
  1. Overall Survival (OS) [ Time Frame: Through study completion, average 2 years ]
    Time from randomization until death from any cause. Patients still alive at the last contact or lost to follow-up will be censored.

  2. Progression free survival [ Time Frame: Through study completion, average 2 years. Evaluated during a total of 2 years (estimated) by CT scan or MR every 12 weeks ]
    Time from from the date of randomization to the date of first documented disease progression according to RECIST 1.1 criteria or the date of death due to any cause. Patients without radiological documentation of progression will be censored on the date of the last control without evidence of progression.

  3. Frequency of adverse events [ Time Frame: Through study completion, average 2 years ]
    Percentage of adverse events, laboratory alterations and treatment discontinuations observed in both treatment arms classified by type and severity (Safety)

  4. Hepatic Progression free survival [ Time Frame: Through study completion, average 2 years. Evaluated during a total of 2 years (estimated) by CT scan or MR every 12 weeks ]
    Time from from the date of randomization to the date of first documented disease progression within the liver according to RECIST 1.1 criteria or the date of death due to any cause. Patients without radiological documentation of progression will be censored on the date of the last control without evidence of progression.

  5. Proportion of patients with liver surgery [ Time Frame: Through study completion, average 2 years. ]
    Proportion of patients undergoing R0 surgery for liver metastases



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients aged ≥ 18 years.
  • Patients with colorectal cancer and exclusive liver metastases with poor prognostic criteria,> 3 lesions and / or size> 5 cm. Patients with a diagnosis of liver metastases with synchronous presentation or with a disease-free interval may be included. If the primary tumor has not been resected, it must be clinically stable.
  • Measurable disease following RECIST version 1.1 criteria
  • Adequate bone marrow function, according to:

    1. Hemoglobin ≥ 9.0 g / dl (patients with hemoglobin <9 g / dl can be transfused before inclusion in the study
    2. Platelet count ≥ 100 x 109 / L
    3. Absolute Neutrophil Count (ANC) ≥ 1.5x 109 / L
  • Adequate liver function, according to:

    1. Serum bilirubin ≤ 1.5 x the upper limit of normal (ULN)
    2. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x ULN.
    3. Alkaline phosphatase ≤ 5 x ULN or ≤10 x ULN in the presence of bone metastases
    4. Adequate renal function, with creatinine levels <1.5 mg / dL. Blood Ureic Nitrogen (BUN)> 50 ml / min.
    5. Albumin> 3.0 g / dL
  • Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
  • Patients capable of understanding the information and giving their written informed consent to participate in the study
  • Women of childbearing potential must commit to sexual abstinence or use of barrier contraceptive methods during the study and must have a negative pregnancy test.

Exclusion Criteria:

  • Extension of the disease> 50% of the liver parenchyma (evaluated by CT performed within the month prior to inclusion)
  • Previous chemotherapy treatment for metastatic colorectal cancer
  • Clinically significant cardiovascular diseases: cerebrovascular accident / stroke (≤ 6 months before inclusion in the trial), myocardial infarction (≤ 6 months before inclusion in the trial), unstable angina, uncontrolled hypertension, congestive heart failure of New York Heart Association (NYHA) grade II or higher or severe cardiac arrhythmia.
  • History of malignancy in the last three years, except for basal cell carcinoma of the skin or carcinoma in situ of the cervix treated appropriately.
  • Altered coagulation (Quick> 50%)
  • Patients with active infectious processes
  • Patients with any of the contraindications specified in the technical data sheet of the study drug or with allergies to some of the drugs used
  • Pregnant or lactating patients
  • Portal thrombosis
  • Severe portal hypertension
  • Extrahepatic metastases

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04595266


Contacts
Layout table for location contacts
Contact: Federico Nepote 934344412 investigacion@mfar.net
Contact: Verónica Roca 934344412 investigacion@mfar.net

Locations
Layout table for location information
Spain
Hospital Parc Taulí Recruiting
Sabadell, Barcelona, Spain
Contact: Principal Investigator Selected by Sponsor       investigacion@mfar.net   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Universitario de Alicante Recruiting
Alicante, Spain
Contact: Principal Investigator Selected by Sponsor       investigacion@mfar.net   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Clínic Recruiting
Barcelona, Spain
Contact: Investigator Selected by Sponsor       investigacion@mfar.net   
Principal Investigator: Investigator Selected by Sponsor         
Hospital de la Santa Creu i Sant Pau Recruiting
Barcelona, Spain
Contact: Principal Investigator Selected by Sponsor       investigacion@mfar.net   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Universitario 12 de Octubre Recruiting
Madrid, Spain
Contact: Principal Investigator Selected by Sponsor       investigacion@mfar.net   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Universitario La Paz Not yet recruiting
Madrid, Spain
Contact: Principal Investigator Selected by Sponsor       investigacion@mfar.net   
Principal Investigator: Principal Investigator Selected by Sponsor         
Complejo Hospitalario de Navarra Recruiting
Pamplona, Spain
Contact: Principal Investigator Selected by Sponsor       investigacion@mfar.net   
Principal Investigator: Principal Investigator Selected by Sponsor         
Hospital Universitario de Canarias Recruiting
Tenerife, Spain
Contact: Principal Investigator Selected by Sponsor       investigacion@mfar.net   
Principal Investigator: Principal Investigator Selected by Sponsor         
Sponsors and Collaborators
Grupo Espanol Multidisciplinario del Cancer Digestivo
Investigators
Layout table for investigator information
Study Chair: Estela Pineda, M.D Hospital Clinic of Barcelona
Study Chair: David Páez, M.D., Ph.D. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Layout table for additonal information
Responsible Party: Grupo Espanol Multidisciplinario del Cancer Digestivo
ClinicalTrials.gov Identifier: NCT04595266    
Other Study ID Numbers: GEMCAD-1802
2020-003795-40 ( EudraCT Number )
First Posted: October 20, 2020    Key Record Dates
Last Update Posted: January 11, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Grupo Espanol Multidisciplinario del Cancer Digestivo:
Colorectal cancer
Chemoembolization
LIVERPEARLS-Irinotecan
Liver metastasis
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Neoplasm Metastasis
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Neoplastic Processes
Pathologic Processes
Leucovorin
Bevacizumab
Fluorouracil
Oxaliplatin
Irinotecan
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Antimetabolites, Antineoplastic
Immunosuppressive Agents